Global Sacral Nerve Stimulation
Global Sacral Nerve Stimulation

Sacral Nerve Stimulation Comprehensive Study by Type (Implantable, External), Application (Urinary & Fecal Incontinence, Urge Incontinence, Chronic Anal Fissure, Others), End User (Hospitals, Ambulatory Surgical Centers, Others) Players and Region - Global Market Outlook to 2025

Sacral Nerve Stimulation Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Dec 2020 Edition 229 Pages 214 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Sacral Nerve Stimulation Market Scope
Sacral nerve stimulation therapy is one of several treatment options for the symptoms of overactive bladder. Sacral nerve stimulation therapy can be used to treat overactive bladder with or without urine leakage and also bladder-emptying problems. It is a reversible treatment that uses a small device to send electrical impulses to nerves located in the lower back. These nerves called the sacral nerves, alter muscles and organs that contribute to bladder control. The electrical stimulation can often successfully eliminate or reduce certain bladder-control problems in some people.

The Sacral Nerve Stimulation market study is segmented by Type (Implantable and External), by Application (Urinary & Fecal Incontinence, Urge Incontinence, Chronic Anal Fissure and Others) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Sacral Nerve Stimulation market throughout the predicted period.

Medtronic (United States), Axonics Modulation Technologies (United States), Nuvectra Corporation (United States), Cogentix Medical (United States), Boston Scientific (United States), St. Jude Medical Inc. (United States), Neuropace Inc. (United States) and Nevro Corporation (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Synapse Biomedical Inc. (United States) and Laborie, Inc (Canada).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global Sacral Nerve Stimulation market by Type, Application and Region.

On the basis of geography, the market of Sacral Nerve Stimulation has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

In Oct 2020, Soin Neuroscience Inc. (SNI) has developed a novel implantable sacral nerve stimulator to treat bladder incontinence. As many as 46 million Americans 40 years of age or older have reported symptoms of urinary incontinence often due to a condition known as overactive bladder, according to the American Urological Association., and In Aug 2020, Medtronic plc announced that it's recently FDA-approved InterStim™ Micro neurostimulator for sacral neuromodulation (SNM) therapy is now available in the United States. Cleveland Clinic performed the first patient implant in the nation with the new device.


Market Trend
  • Availability of Electrical Stimulators

Market Drivers
  • Increasing Cases of Urge Incontinence, such as Urinary Tract Infection (UTI)
  • Rising Number of Patients Suffering from Overactive Bladder (OAB) and Fecal Incontinence

Opportunities
  • Increase In Research and Development Investments
  • Increasing Chronic Pain among the Individuals
  • Growing Demand from Emerging Market

Restraints
  • Stringent Regulation for Device Approval

Challenges
  • Lack of Knowledge on the Occurrence and Management of Suboptimal Therapeutic Effects
  • Intense Competition among Competitor


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Sacral Nerve Stimulation Device Manufacturer, Sacral Nerve Stimulation Devices Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Implantable
  • External
By Application
  • Urinary & Fecal Incontinence
  • Urge Incontinence
  • Chronic Anal Fissure
  • Others
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Cases of Urge Incontinence, such as Urinary Tract Infection (UTI)
      • 3.2.2. Rising Number of Patients Suffering from Overactive Bladder (OAB) and Fecal Incontinence
    • 3.3. Market Challenges
      • 3.3.1. Lack of Knowledge on the Occurrence and Management of Suboptimal Therapeutic Effects
      • 3.3.2. Intense Competition among Competitor
    • 3.4. Market Trends
      • 3.4.1. Availability of Electrical Stimulators
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Sacral Nerve Stimulation, by Type, Application, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Sacral Nerve Stimulation (Value)
      • 5.2.1. Global Sacral Nerve Stimulation by: Type (Value)
        • 5.2.1.1. Implantable
        • 5.2.1.2. External
      • 5.2.2. Global Sacral Nerve Stimulation by: Application (Value)
        • 5.2.2.1. Urinary & Fecal Incontinence
        • 5.2.2.2. Urge Incontinence
        • 5.2.2.3. Chronic Anal Fissure
        • 5.2.2.4. Others
      • 5.2.3. Global Sacral Nerve Stimulation by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Ambulatory Surgical Centers
        • 5.2.3.3. Others
      • 5.2.4. Global Sacral Nerve Stimulation Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Sacral Nerve Stimulation: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Medtronic (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Axonics Modulation Technologies (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Nuvectra Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cogentix Medical (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Boston Scientific (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. St. Jude Medical Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Neuropace Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Nevro Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Sacral Nerve Stimulation Sale, by Type, Application, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Sacral Nerve Stimulation (Value)
      • 7.2.1. Global Sacral Nerve Stimulation by: Type (Value)
        • 7.2.1.1. Implantable
        • 7.2.1.2. External
      • 7.2.2. Global Sacral Nerve Stimulation by: Application (Value)
        • 7.2.2.1. Urinary & Fecal Incontinence
        • 7.2.2.2. Urge Incontinence
        • 7.2.2.3. Chronic Anal Fissure
        • 7.2.2.4. Others
      • 7.2.3. Global Sacral Nerve Stimulation by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Ambulatory Surgical Centers
        • 7.2.3.3. Others
      • 7.2.4. Global Sacral Nerve Stimulation Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Sacral Nerve Stimulation: by Type(USD Million)
  • Table 2. Sacral Nerve Stimulation Implantable , by Region USD Million (2014-2019)
  • Table 3. Sacral Nerve Stimulation External , by Region USD Million (2014-2019)
  • Table 4. Sacral Nerve Stimulation: by Application(USD Million)
  • Table 5. Sacral Nerve Stimulation Urinary & Fecal Incontinence , by Region USD Million (2014-2019)
  • Table 6. Sacral Nerve Stimulation Urge Incontinence , by Region USD Million (2014-2019)
  • Table 7. Sacral Nerve Stimulation Chronic Anal Fissure , by Region USD Million (2014-2019)
  • Table 8. Sacral Nerve Stimulation Others , by Region USD Million (2014-2019)
  • Table 9. Sacral Nerve Stimulation: by End User(USD Million)
  • Table 10. Sacral Nerve Stimulation Hospitals , by Region USD Million (2014-2019)
  • Table 11. Sacral Nerve Stimulation Ambulatory Surgical Centers , by Region USD Million (2014-2019)
  • Table 12. Sacral Nerve Stimulation Others , by Region USD Million (2014-2019)
  • Table 13. South America Sacral Nerve Stimulation, by Country USD Million (2014-2019)
  • Table 14. South America Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 15. South America Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 16. South America Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 17. Brazil Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 18. Brazil Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 19. Brazil Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 20. Argentina Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 21. Argentina Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 22. Argentina Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 23. Rest of South America Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 24. Rest of South America Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 25. Rest of South America Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 26. Asia Pacific Sacral Nerve Stimulation, by Country USD Million (2014-2019)
  • Table 27. Asia Pacific Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 28. Asia Pacific Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 29. Asia Pacific Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 30. China Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 31. China Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 32. China Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 33. Japan Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 34. Japan Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 35. Japan Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 36. India Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 37. India Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 38. India Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 39. South Korea Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 40. South Korea Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 41. South Korea Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 42. Taiwan Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 43. Taiwan Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 44. Taiwan Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 45. Australia Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 46. Australia Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 47. Australia Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 48. Rest of Asia-Pacific Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 49. Rest of Asia-Pacific Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 50. Rest of Asia-Pacific Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 51. Europe Sacral Nerve Stimulation, by Country USD Million (2014-2019)
  • Table 52. Europe Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 53. Europe Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 54. Europe Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 55. Germany Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 56. Germany Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 57. Germany Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 58. France Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 59. France Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 60. France Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 61. Italy Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 62. Italy Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 63. Italy Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 64. United Kingdom Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 65. United Kingdom Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 66. United Kingdom Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 67. Netherlands Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 68. Netherlands Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 69. Netherlands Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 70. Rest of Europe Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 71. Rest of Europe Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 72. Rest of Europe Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 73. MEA Sacral Nerve Stimulation, by Country USD Million (2014-2019)
  • Table 74. MEA Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 75. MEA Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 76. MEA Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 77. Middle East Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 78. Middle East Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 79. Middle East Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 80. Africa Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 81. Africa Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 82. Africa Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 83. North America Sacral Nerve Stimulation, by Country USD Million (2014-2019)
  • Table 84. North America Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 85. North America Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 86. North America Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 87. United States Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 88. United States Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 89. United States Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 90. Canada Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 91. Canada Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 92. Canada Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 93. Mexico Sacral Nerve Stimulation, by Type USD Million (2014-2019)
  • Table 94. Mexico Sacral Nerve Stimulation, by Application USD Million (2014-2019)
  • Table 95. Mexico Sacral Nerve Stimulation, by End User USD Million (2014-2019)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Sacral Nerve Stimulation: by Type(USD Million)
  • Table 105. Sacral Nerve Stimulation Implantable , by Region USD Million (2020-2025)
  • Table 106. Sacral Nerve Stimulation External , by Region USD Million (2020-2025)
  • Table 107. Sacral Nerve Stimulation: by Application(USD Million)
  • Table 108. Sacral Nerve Stimulation Urinary & Fecal Incontinence , by Region USD Million (2020-2025)
  • Table 109. Sacral Nerve Stimulation Urge Incontinence , by Region USD Million (2020-2025)
  • Table 110. Sacral Nerve Stimulation Chronic Anal Fissure , by Region USD Million (2020-2025)
  • Table 111. Sacral Nerve Stimulation Others , by Region USD Million (2020-2025)
  • Table 112. Sacral Nerve Stimulation: by End User(USD Million)
  • Table 113. Sacral Nerve Stimulation Hospitals , by Region USD Million (2020-2025)
  • Table 114. Sacral Nerve Stimulation Ambulatory Surgical Centers , by Region USD Million (2020-2025)
  • Table 115. Sacral Nerve Stimulation Others , by Region USD Million (2020-2025)
  • Table 116. South America Sacral Nerve Stimulation, by Country USD Million (2020-2025)
  • Table 117. South America Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 118. South America Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 119. South America Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 120. Brazil Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 121. Brazil Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 122. Brazil Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 123. Argentina Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 124. Argentina Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 125. Argentina Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 126. Rest of South America Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 127. Rest of South America Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 128. Rest of South America Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 129. Asia Pacific Sacral Nerve Stimulation, by Country USD Million (2020-2025)
  • Table 130. Asia Pacific Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 131. Asia Pacific Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 132. Asia Pacific Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 133. China Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 134. China Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 135. China Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 136. Japan Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 137. Japan Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 138. Japan Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 139. India Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 140. India Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 141. India Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 142. South Korea Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 143. South Korea Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 144. South Korea Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 145. Taiwan Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 146. Taiwan Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 147. Taiwan Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 148. Australia Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 149. Australia Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 150. Australia Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 151. Rest of Asia-Pacific Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 152. Rest of Asia-Pacific Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 153. Rest of Asia-Pacific Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 154. Europe Sacral Nerve Stimulation, by Country USD Million (2020-2025)
  • Table 155. Europe Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 156. Europe Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 157. Europe Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 158. Germany Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 159. Germany Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 160. Germany Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 161. France Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 162. France Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 163. France Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 164. Italy Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 165. Italy Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 166. Italy Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 167. United Kingdom Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 168. United Kingdom Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 169. United Kingdom Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 170. Netherlands Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 171. Netherlands Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 172. Netherlands Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 173. Rest of Europe Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 174. Rest of Europe Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 175. Rest of Europe Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 176. MEA Sacral Nerve Stimulation, by Country USD Million (2020-2025)
  • Table 177. MEA Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 178. MEA Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 179. MEA Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 180. Middle East Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 181. Middle East Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 182. Middle East Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 183. Africa Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 184. Africa Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 185. Africa Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 186. North America Sacral Nerve Stimulation, by Country USD Million (2020-2025)
  • Table 187. North America Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 188. North America Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 189. North America Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 190. United States Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 191. United States Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 192. United States Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 193. Canada Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 194. Canada Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 195. Canada Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 196. Mexico Sacral Nerve Stimulation, by Type USD Million (2020-2025)
  • Table 197. Mexico Sacral Nerve Stimulation, by Application USD Million (2020-2025)
  • Table 198. Mexico Sacral Nerve Stimulation, by End User USD Million (2020-2025)
  • Table 199. Research Programs/Design for This Report
  • Table 200. Key Data Information from Secondary Sources
  • Table 201. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Sacral Nerve Stimulation: by Type USD Million (2014-2019)
  • Figure 5. Global Sacral Nerve Stimulation: by Application USD Million (2014-2019)
  • Figure 6. Global Sacral Nerve Stimulation: by End User USD Million (2014-2019)
  • Figure 7. South America Sacral Nerve Stimulation Share (%), by Country
  • Figure 8. Asia Pacific Sacral Nerve Stimulation Share (%), by Country
  • Figure 9. Europe Sacral Nerve Stimulation Share (%), by Country
  • Figure 10. MEA Sacral Nerve Stimulation Share (%), by Country
  • Figure 11. North America Sacral Nerve Stimulation Share (%), by Country
  • Figure 12. Global Sacral Nerve Stimulation share by Players 2019 (%)
  • Figure 13. Global Sacral Nerve Stimulation share by Players (Top 3) 2019(%)
  • Figure 14. Global Sacral Nerve Stimulation share by Players (Top 5) 2019(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Medtronic (United States) Revenue, Net Income and Gross profit
  • Figure 17. Medtronic (United States) Revenue: by Geography 2019
  • Figure 18. Axonics Modulation Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 19. Axonics Modulation Technologies (United States) Revenue: by Geography 2019
  • Figure 20. Nuvectra Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 21. Nuvectra Corporation (United States) Revenue: by Geography 2019
  • Figure 22. Cogentix Medical (United States) Revenue, Net Income and Gross profit
  • Figure 23. Cogentix Medical (United States) Revenue: by Geography 2019
  • Figure 24. Boston Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 25. Boston Scientific (United States) Revenue: by Geography 2019
  • Figure 26. St. Jude Medical Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. St. Jude Medical Inc. (United States) Revenue: by Geography 2019
  • Figure 28. Neuropace Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Neuropace Inc. (United States) Revenue: by Geography 2019
  • Figure 30. Nevro Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 31. Nevro Corporation (United States) Revenue: by Geography 2019
  • Figure 32. Global Sacral Nerve Stimulation: by Type USD Million (2020-2025)
  • Figure 33. Global Sacral Nerve Stimulation: by Application USD Million (2020-2025)
  • Figure 34. Global Sacral Nerve Stimulation: by End User USD Million (2020-2025)
  • Figure 35. South America Sacral Nerve Stimulation Share (%), by Country
  • Figure 36. Asia Pacific Sacral Nerve Stimulation Share (%), by Country
  • Figure 37. Europe Sacral Nerve Stimulation Share (%), by Country
  • Figure 38. MEA Sacral Nerve Stimulation Share (%), by Country
  • Figure 39. North America Sacral Nerve Stimulation Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Medtronic (United States)
  • Axonics Modulation Technologies (United States)
  • Nuvectra Corporation (United States)
  • Cogentix Medical (United States)
  • Boston Scientific (United States)
  • St. Jude Medical Inc. (United States)
  • Neuropace Inc. (United States)
  • Nevro Corporation (United States)
Additional players considered in the study are as follows:
Synapse Biomedical Inc. (United States) , Laborie, Inc (Canada)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation